Competition and Market Dynamics - The company faces intense competition in the home health, hospice, and durable medical equipment industries, with numerous competitors having greater financial resources [148]. - Managed care organizations are consolidating, which could adversely affect the company's ability to maintain relationships with existing patient referral sources and impact financial performance [152]. - The company seeks to diversify payer sources through managed care contracts, but failure to secure favorable contracts could materially impact financial performance [199]. - National public health emergencies, such as pandemics, could lead to decreased demand for services and increased operational costs, adversely affecting financial condition [200]. - Labor shortages in the healthcare industry may increase recruitment costs and reduce profitability, impacting the company's ability to meet patient demand [203]. Reimbursement and Funding Risks - The company relies heavily on Medicare and Medicaid for funding, and changes in reimbursement rates could materially affect revenue and profitability [158]. - The One Big Beautiful Bill Act (OBBBA) passed in 2025 includes funding cuts to Medicaid, which may lead to lower reimbursement for the company's services [159]. - Medicare reimbursement has been subject to a 2% reduction through sequestration since July 1, 2022, which could impact financial results [163]. - CMS implemented a new payment system (PDGM) on January 1, 2020, which changed the payment period from 60 days to 30 days, potentially affecting reimbursement rates [164]. - The Review Choice Demonstration (RCD) project could delay or reduce Medicare reimbursement if the company fails to comply with its requirements [165]. - The Consolidated Appropriations Act includes provisions that could impact Medicare benefit payments, with a 2% mandatory sequestration effective January 1, 2025 [166]. - A final rule released by CMS on November 28, 2025, cuts Medicare reimbursement rates by 1.3%, which may adversely affect the company's financial position [168]. - The company faces risks related to reimbursement rates from Medicare and Medicaid, which are fixed and established through legislation, impacting profitability [171]. - Value-based purchasing programs are becoming more common, with potential impacts on reimbursement based on quality of care and outcomes [172]. - CMS aims to have all fee-for-service Medicare beneficiaries in a care relationship with accountability for quality and total cost of care by 2030, indicating a shift towards value-based care [173]. - Changes in healthcare regulations, particularly regarding Medicare and Medicaid, could adversely impact customer payments, affecting the company's financial condition and cash flows [190]. - A decrease in Medicare reimbursement rates, as indicated by the 2026 HH Rule, could have a material adverse effect on the company's financial results [192]. - Quality reporting requirements for hospice services may lead to a 2% reduction in Medicare reimbursement if compliance is not met, impacting financial performance [194]. - The company is subject to annual Medicare caps for hospice operations, and exceeding these caps could necessitate reimbursement to Medicare, adversely affecting financial results [198]. - Adverse developments in the U.S. could lead to a reduction in federal government expenditures, including funding for Medicare and Medicaid, which may materially affect the company's financial condition and cash flows [205]. - The company faces increased pricing pressure and potential reimbursement rate cuts from Medicare and Medicaid due to economic downturns, which could adversely impact its business [204]. Financial Position and Capital Structure - The company has a substantial amount of indebtedness, with $1,487 million principal amount outstanding under all borrowings as of January 3, 2026 [221]. - The company has approximately $225.5 million borrowing availability under its Revolving Credit Facility and approximately $110.0 million borrowing availability on its Securitization Facility as of January 3, 2026 [221]. - The company’s high leverage may limit its ability to pursue strategic alternatives and react to changes in the business environment [222]. - The company's outstanding variable rate indebtedness was $1,487 million as of January 3, 2026, exposing it to interest rate risk due to fluctuations in the secured overnight financing rate (SOFR) [228]. - Goodwill and intangible assets accounted for approximately 60% of total assets on the balance sheet as of January 3, 2026, indicating potential risks related to impairment [242]. - The company has recorded a valuation allowance against certain state and federal NOLs determined not to be more likely than not to be utilized in the future [251]. - The company recorded an interest expense carryover of $371.6 million for federal and state purposes as of January 3, 2026 [251]. Operational and Compliance Challenges - Delays in billing and collections could adversely affect the company's liquidity and financial position, particularly during integration processes [175]. - The timing of payments under Medicare and Medicaid managed care programs is slower than traditional models, complicating cash flow management [178]. - Changes in estimates of collectability or delays in accounts receivable could negatively impact results of operations and liquidity [179]. - Cybersecurity threats are increasing in frequency and complexity, posing risks to the company's financial position and operations [181]. - Any cybersecurity incidents could result in significant liabilities, fines, and reputational damage, adversely affecting the company's business [184]. - The company may face significant capital expenditures to protect against cybersecurity threats, which could lead to material disruptions and loss of sensitive information [185]. - Past incidents of cybersecurity breaches have exposed the company to regulatory penalties, litigation, and increased operational expenses, potentially impacting financial position and liquidity [186]. - The use of artificial intelligence (AI) poses risks related to confidentiality and inaccurate outputs, which could adversely affect business operations and decision-making [187]. - The implementation of new or upgraded business and information technology systems may disrupt operations and adversely affect financial results [208]. - The company must comply with extensive conditions of participation in the Medicare program, and failure to do so could result in termination from Medicare, adversely affecting cash flow [212]. - The company is subject to ongoing audits and investigations by federal and state agencies, which could result in significant fines and penalties [268]. - The company is subject to extensive regulations that govern its relationships with physicians and other referral sources, which could impact its operations [270]. Governance and Shareholder Considerations - The company does not intend to pay dividends for the foreseeable future, opting to retain all available funds for business growth [292]. - The company qualifies as a "controlled company," with Bain Capital L.P. and J.H. Whitney Capital Partners collectively owning 57.7% of outstanding common stock as of January 3, 2026, which may affect governance and attractiveness to investors [293]. - The company faces potential conflicts of interest due to its Sponsors' ability to influence business decisions and pursue competing opportunities [294]. - The company must comply with Section 404 of the Sarbanes-Oxley Act, which requires annual assessments of internal control effectiveness, incurring substantial expenses [296]. - There is a risk of material weaknesses in internal controls that could adversely affect financial reporting and investor confidence [297]. - Anti-takeover provisions in the company's governing documents may limit stockholder actions and affect the market price of common stock [298]. - The company has opted out of Section 203 of the Delaware General Corporation Law, which could delay or prevent certain business combinations [299]. - The company’s Amended Charter limits the ability of stockholders to bring claims in favorable judicial forums, potentially discouraging lawsuits [302]. - The company has approximately 800 million shares of authorized but unissued common stock, which could lead to dilution for existing shareholders if additional shares are issued [287]. - The company has filed registration statements on Form S-8 to register shares of common stock issuable under its incentive plans, which may lead to dilution [287]. - The company has a currently effective shelf registration statement on Form S-3 allowing it to offer and sell up to $400 million of various securities, which could dilute existing shareholders [288]. Legal and Regulatory Risks - The company may face significant penalties for non-compliance with various federal and state laws regarding data privacy and security, which could adversely affect its business [284]. - The company is required to offer a minimum level of health coverage for 95% of its full-time employees in 2024 or face an annual penalty [286]. - The company is exposed to liabilities from potential violations of the Anti-Kickback Statute and Stark Law, which could lead to civil and criminal penalties [274]. - The company has incurred and expects to continue incurring additional costs to comply with the California Consumer Privacy Act (CCPA) and similar regulations [284]. - The company is monitoring legal developments in data privacy and security regulations, as evolving laws may have a material adverse effect on its operations [284]. - The company faces risks related to changes in tax laws and regulations that could adversely affect its financial condition and cash flows [252]. - The company is impacted by healthcare reforms that may change the nature of its services and payment methods, potentially affecting its revenue [259].

Financial Performance - For 2025, net income attributable to common stockholders decreased to $75,000 from $2,690,000 in 2024, primarily due to a $2,976,000 increase in corporate expenses and a $2,519,000 decrease in equity earnings from joint ventures [264]. - Net income for 2025 was $71,000, a significant decrease from $2,688,000 in 2024 and $3,265,000 in 2023 [360]. - Adjusted EBITDA increased to $25,256,000 in 2025, up from $23,378,000 in 2024 and $21,386,000 in 2023, reflecting a growth of 8% year-over-year [360]. - Total net operating income for Commercial/Industrial was $8,008,000 in 2025, down from $9,036,000 in 2024, indicating a decline of 11.4% [363]. - Earnings from unconsolidated joint ventures decreased to $14,561,000 in 2025 from $18,874,000 in 2024, representing a decline of 22.3% [366]. - The company reported a total depreciation and amortization of $13,004,000 in 2025, an increase from $11,638,000 in 2024 [360]. - The company incurred shareholder activism expenses of $3,399,000 in 2025, which impacted comparability [360]. Revenue and Segment Performance - Commercial/industrial revenues increased by 20% year-over-year to $15,006,000 in 2025, driven by land sales within TRCC, including $3,737,000 from two land sales [280]. - The commercial/industrial segment's operating income rose to $7,004,000 in 2025, up from $4,642,000 in 2024, reflecting improved profitability from land sales [279]. - The farming segment saw a $3,514,000 improvement in operating results in 2025, attributed to higher pistachio revenues [264]. - Total profit from land sales for 2025 was $1,875,000, contributing to the overall revenue growth in the commercial/industrial segment [264]. - Multifamily revenues for the year ended December 31, 2025, were $732,000, primarily from rental income during the initial lease-up phase of Terra Vista at Tejon, which began leasing in May 2025 [292]. - Resort/residential segment expenses decreased by $338,000, or 13%, to $2,277,000 in 2025 compared to $2,615,000 in 2024, mainly due to lower professional service fees and payroll costs [293]. - Mineral resources segment revenues decreased by $578,000, or 6%, to $9,636,000 in 2025, attributed to lower oil and natural gas production volumes and pricing [299]. - Total ranch operations revenues increased by $284,000, or 5%, from $5,195,000 in 2024 to $5,479,000 in 2025, mainly due to higher game management and other revenue [312]. Expenses and Costs - Corporate general and administrative costs increased by $2,976,000, or 26.8%, to $14,068,000 during 2025 compared to $11,092,000 in 2024, largely due to higher shareholder expenses [311]. - Farming segment expenses rose by $1,299,000, or 7%, from $17,551,000 in 2024 to $18,850,000 in 2025, primarily due to higher crop-related costs associated with the 2025 pistachio harvest [302]. - Ranch operations expenses increased by $397,000, or 8%, from $4,864,000 in 2024 to $5,261,000 in 2025, primarily due to higher operating expenses [312]. - Total mineral resources expenses decreased by $245,000, or 3%, to $6,807,000 in 2025, reflecting lower costs associated with reduced water sales [299]. Investments and Capital Expenditures - The company plans to commence construction of a 510,385 square-foot industrial building through a joint venture with Dedeaux Properties in 2026 [283]. - The estimated capital investment for 2026 includes approximately $16,857,000 for development costs at TRCC-East and $5,254,000 for developing olive and almond orchards [333]. - Investing activities used $62,306,000 in 2025, primarily driven by capital expenditures of $63,210,000 related to real estate [327]. Debt and Financing - The company entered into a Revolving Credit Facility providing $160,000,000 in revolving credit and a $15,000,000 letter of credit sub-facility, with interest-only payments required until maturity on January 1, 2029 [339][340]. - The company paid off $47,078,564 in existing debt using funds from the Revolving Credit Facility, which will be used for working capital and future construction projects [341]. - As of December 31, 2025, total capitalization at book value was $584,498,000, with a debt-to-total-capitalization ratio of approximately 16.1%, up from 12.0% in 2024 [338]. - The outstanding balance on the revolving line of credit was $93,942,000 as of December 31, 2025, with an effective interest rate of 6.15% [370]. - The company expects to secure additional funding through debt financing, joint ventures, asset sales, or issuance of common stock to meet capital requirements for land development [351]. Future Outlook - The company anticipates achieving stabilized occupancy for the multifamily segment in 2026, which is expected to improve operating income compared to 2025 [292]. - The long-term business plan for the development of MV, Grapevine, and Centennial remains unchanged, with a focus on obtaining development capital and enhancing land value [295]. - The company expects to continue investing in vertical development within its active commercial and industrial segments to enhance shareholder value [322].

Sales and Revenue - Jewelry sales accounted for 10.2% of consolidated net sales in fiscal year 2026[26] - The second half of the fiscal year historically accounts for a significant portion of net sales, with 56.3% in 2026, 55.4% in 2025, and 54.2% in 2024[48] - For the fiscal year ended January 31, 2026, licensed brands represented 58.3% of the Company's net sales, indicating significant reliance on these agreements for revenue generation[122] - The Company's International operations accounted for 34.1% of total net sales in Europe, 9.7% in the Americas (excluding the U.S.), 7.0% in Asia, and 5.9% in the Middle East for fiscal 2026[201] Marketing and Brand Strategy - The Company plans to launch a new collection under the Kate Spade New York brand in spring 2027[16] - The Company focuses on expanding its digital marketing and online reach, including social media and influencer partnerships[41] - The Company has a selective licensing strategy, entering long-term agreements with powerful brands[15] - The Company’s owned brands generally earn higher gross margins compared to licensed brands, with e-commerce gross margins also exceeding those of traditional wholesale[205] Financial Performance and Risks - The Company had unfilled orders of $46.9 million as of March 13, 2026, compared to $56.8 million on April 11, 2025, and $41.0 million on March 20, 2024, indicating a decrease in backlog[49] - Adverse economic conditions, including declines in consumer confidence and spending, could materially affect the Company's operating results, particularly for discretionary items[86][87] - The United States has imposed additional tariffs on imported goods, which could increase product and input costs, disrupt sourcing, and adversely affect margins[96][99] - The Company is subject to foreign currency exchange rate risk, with significant inventory purchases in Swiss Francs and sales in various foreign currencies, impacting future results of operations[95] Operational Structure - The Company operates in two segments: Watch and Accessory Brands and Company Stores[42] - The Company operates 53 retail outlet locations in the U.S. and four in Canada, along with an online outlet store, providing effective channels for selling current and discontinued models[47] - The Company employs a flexible manufacturing model, relying on independent manufacturers to meet market demand while maintaining high-quality standards[55] Employee and Workforce - Approximately 37% of the Company's non-retail employees have been with the Company for over 10 years, indicating strong employee retention[70] - The Company has a global workforce of 1,386 employees, with 991 full-time, 363 part-time, and 32 temporary employees as of January 31, 2026[69] Legal and Compliance - The Company actively protects its intellectual property rights and is involved in litigation to enforce these rights when necessary[66] - The Company operates in numerous foreign jurisdictions and is subject to anti-corruption laws, which could result in significant penalties if violated[94] - The Company is involved in legal proceedings that may affect its financial condition, but the resolution of these matters is not expected to materially impact future results[185] Supply Chain and Production - The Company relies on independent manufacturers, and any loss or disruption in supply could adversely affect customer relations and net sales[145] - The Company maintains service facilities worldwide, including four owned facilities and several authorized independent service centers for warranty repairs[52] Cybersecurity and Technology - Cybersecurity risks pose a threat to the Company's information systems, potentially leading to lost sales and damage to customer relationships[150] - E-commerce operations are at risk from system failures and disruptions, which could lead to lost sales and harm the Company's reputation[134] Financial Management - The Company must secure financing on favorable terms to maintain its financial condition, as increased borrowing costs could adversely impact operations[164] - The Company expects to incur significant charges from restructuring and optimization initiatives, which could reduce operating income and net income[149] Market Competition - The Company faces intense competition in the watch industry, including from smart watches, which could adversely affect its market position and financial results[113] - Regulatory changes and a shifting marketing environment may hinder the Company's ability to penetrate key market segments, potentially leading to a loss of market share and revenue[120] Environmental and Social Responsibility - The Company is committed to community engagement, sponsoring The Movado Group Foundation, which supports philanthropic campaigns in the U.S.[79] - The Company is subject to environmental risks, including climate change, which could lead to increased operational expenses and affect profitability[137]

Financial Performance - EquipmentShare reported significant growth in revenue, achieving $500 million in total revenue for the fiscal year, representing a 25% increase year-over-year[9]. - The management has set a performance guidance of $575 million in revenue for the next fiscal year, reflecting continued optimism about market conditions[9]. User Growth and Demand - The company expanded its user base to 150,000 active users, a 30% increase compared to the previous year, indicating strong demand for its services[10]. - EquipmentShare anticipates a 10% growth in rental rates due to increased demand and reduced competition in the market[10]. Technology and Platform Development - EquipmentShare's cloud-based platform, T3, has seen a 40% increase in usage, reflecting the growing reliance on technology in the construction equipment rental industry[10]. - EquipmentShare's investment in cybersecurity measures has increased by 20% to safeguard user data and enhance platform security[10]. Expansion and Market Strategy - The company plans to open 20 new branch locations in the next fiscal year, aiming to enhance its market presence and accessibility[10]. - EquipmentShare is actively pursuing strategic acquisitions to bolster its market position, with a target of acquiring at least two companies in the next 12 months[10]. Fleet Growth and Sales Projections - EquipmentShare's innovative capital-light fleet growth model, known as the "OWN Program," is expected to contribute to a projected 15% increase in equipment sales in the upcoming year[10]. Competitive Landscape - The company faces competitive pressures that could impact market share, with a focus on maintaining strong supplier relationships to mitigate risks[10].

Dividend Distribution and Restrictions - As of December 31, 2025, the maximum amount available for dividend distribution from the Bank to the Company was approximately $46 million[72]. - The Company is subject to restrictions on dividends and stock repurchases due to California law and Federal Reserve policies[69][73]. - The Bank is required to maintain certain capital levels under Basel III capital rules, impacting its ability to pay dividends[72]. Regulatory Compliance and Risks - The Company must comply with various consumer protection laws, which may lead to increased compliance costs[82][83]. - The Company is subject to potential enforcement actions for unsafe practices or regulatory violations, which could affect its operations[88]. - The Bank's lending practices are guided by federal regulations to ensure compliance and mitigate risks associated with commercial real estate lending[78]. Financial Performance and Expenses - The Bank's FDIC insurance expense totaled $871 thousand for 2025[79]. - The FRB's monetary policy significantly influences the Company's profitability, primarily through interest rate spreads[90]. Lending Limits and Ratings - The Bank's limit on aggregate secured loans-to-one-borrower was $67 million and unsecured loans-to-one-borrower was $40 million as of December 31, 2025[74]. - The Bank's most recent Community Reinvestment Act rating was "Satisfactory," which is crucial for future growth through acquisitions or new branches[75].

Financial Performance - Q4 2025 revenue was $5.8M, unchanged from Q4 2024 and a 1% increase from Q3 2025[5] - Full year 2025 total revenue was $22.6M, a 2% decrease from $23.1M in 2024[9] - Revenues for Q4 2025 were $5,799 million, a slight decrease of 0.5% compared to $5,826 million in Q4 2024[31] - Gross profit for the year ended December 31, 2025, was $17,314 million, down from $17,440 million in 2024, reflecting a decrease of 0.7%[31] - Cash provided by operating activities for the year 2025 was $558 million, compared to $3,160 million in 2024, indicating a decline in cash flow[33] Profitability Metrics - Gross margin for Q4 2025 increased to 77%, up from 75% in Q4 2024[5] - Full year 2025 gross margin was 77% of revenue, compared to 76% in 2024[9] - Adjusted EBITDA for Q4 2025 was $0.9M, or 15% of revenue, consistent with Q4 2024[6] - Operating loss for 2025 was $1.9M, significantly reduced from $16.3M in 2024[9] - Operating loss for Q4 2025 was $(761) million, significantly improved from $(14,322) million in Q4 2024[31] - Net loss from continuing operations for Q4 2025 was $0.5M, or $0.13 per diluted share, compared to $10.9M, or $2.85 per diluted share, in Q4 2024[6] - The company reported a net loss from continuing operations of $1,558,000, or $0.40 per diluted share for the year ended December 31, 2025, compared to a loss of $13,281,000, or $3.47 per diluted share in 2024[17] - Net income for the year ended December 31, 2025, was $4,291 million, a recovery from a net loss of $(10,793) million in 2024[33] Cash Flow and Assets - Free cash flow from continuing operations for the three months ended December 31, 2025, was $109,000, down from $293,000 in the same period of 2024[18] - Adjusted free cash flow from continuing operations for the year ended December 31, 2025, was $1,266,000, compared to $2,786,000 in 2024[18] - Total assets decreased to $41,992,000 as of December 31, 2025, from $50,638,000 in 2024[29] - Cash and cash equivalents at the end of 2025 were $3,025 million, down from $4,103 million at the end of 2024[33] Liabilities and Shareholder Information - The company’s total liabilities decreased to $11,647,000 as of December 31, 2025, from $25,412,000 in 2024[29] - The weighted average number of common shares outstanding for the year ended December 31, 2025, was 3,859,000, compared to 3,829,000 in 2024[17] - The weighted average number of common shares outstanding for Q4 2025 was 3,864 million, slightly up from 3,837 million in Q4 2024[31] Impairment and Gains - The company reported an impairment loss of $250,000 for the year ended December 31, 2025, compared to $14,150,000 in 2024[17] - The company incurred an impairment loss of $250 million in 2025, compared to $14,150 million in 2024[31] - The company reported a gain on the disposal of business amounting to $(8,974) million in 2025, with no such gain reported in 2024[33] Future Plans and Developments - The company trained over 1,800 students across 60-plus universities on its ACCESS PR platform in the past 90 days[3] - The company plans to launch new products, including Access Verified and a social monitoring platform, expected to generate incremental revenue starting Q2 2026[2] - The company expects to launch a social monitoring platform with an AI Interactive Distribution Report before the end of March 2026[25] - The company anticipates generating incremental revenue through premium subscription tiers and per release pricing for new offerings starting in Q2 2026[25]

Clinical Development - The company has developed late-stage clinical product candidates, including setrusumab for osteogenesis imperfecta (OI) and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), both of which have received orphan designations from regulatory authorities [533]. - The company has successfully completed large, randomized Phase 2 clinical trials for four product candidates and announced results from two Phase 3 studies for setrusumab in OI [534]. - Research and development expenses are expected to include costs associated with the preparation of alvelestat for the Phase 3 study, including regulatory and manufacturing activities [541]. - The company anticipates costs related to the collaboration with Ultragenyx for setrusumab and potential future clinical trials for alvelestat [593]. Financial Performance - Revenue for the year ended December 31, 2025 was $0.5 million, a one-time milestone payment from ReproNovo, compared to no revenue in 2024 [565]. - Total operating expenses decreased by $3.2 million from $47.4 million in 2024 to $40.1 million in 2025 [568]. - Research and development (R&D) expenses decreased by $3.2 million from $20.9 million in 2024 to $17.8 million in 2025, primarily due to reductions in expenses for alvelestat and etigilimab [568][569]. - General and administrative expenses decreased by $3.4 million from $26.4 million in 2024 to $23.0 million in 2025, attributed to lower cash bonus accruals and professional fees [571]. - Interest income decreased by $0.9 million from $3.0 million in 2024 to $2.2 million in 2025 due to lower interest rates and cash balances [574]. - The accumulated deficit as of December 31, 2025 was $501.0 million, with expectations of continued significant operating losses [589]. Taxation and Losses - As of December 31, 2025, the company reported cumulative carry-forward U.K. tax losses of $64.1 million and U.S. federal tax losses of approximately $67.0 million, with $20.5 million of these losses able to be carried forward indefinitely [553][561]. - The U.K. corporation tax rate applied for 2025 was 25%, and the company has not paid U.K. corporation tax since inception, except in 2021 [560]. - The company has recorded the entire benefit from U.K. R&D tax credits as a benefit included in net loss before income tax, which is not reflected as part of the income tax provision [556]. - The company expects to claim under the Merged Scheme for R&D tax credits from 2025 onward, as it does not qualify as an R&D intensive company for 2025 [557]. Cash Flow and Funding - Net cash used in operating activities was $31.0 million in 2025, a decrease of $1.9 million from $32.8 million in 2024 [587]. - Net cash provided by financing activities was $0.3 million in 2025, a decrease of $45.8 million from $46.1 million in 2024, reflecting no significant financing activities in 2025 [588]. - The company anticipates needing additional external funding to complete development plans and potentially commercialize selected rare disease products [580]. - The company may need to obtain substantial additional funds to achieve business objectives, which may not be available on acceptable terms [595]. - As of December 31, 2025, the company held cash and cash equivalents of $41.0 million [607]. - The company expects existing cash and cash equivalents to fund clinical trials and operating expenses into mid-2027 [591]. Currency and Inflation - The foreign currency translation adjustment for 2025 was a gain of $8.0 million, compared to a loss of $1.4 million in 2024, reflecting changes in currency value impacts [579]. - For the year ended December 31, 2025, there was an unrealized gain of $8.0 million on foreign currency translation compared to an unrealized loss of $1.4 million for the year ended December 31, 2024 [608]. - The company has not entered into foreign exchange contracts to hedge against fluctuations but maintains cash in U.S. dollars for anticipated commitments [609]. - Inflation has increased operating expenses, but it has not had a material effect on the company's financial condition during the year ended December 31, 2025 [610].

Financial Performance - The company incurred a net loss of $27.2 million in 2023, $10.6 million in 2024, and $6.1 million in 2025, with an accumulated deficit of $237 million as of December 31, 2025[38]. - The company anticipates ongoing losses as it invests in research and development and seeks regulatory approvals for its product candidates[38]. - The company expects continued significant expenses and operating losses over the next several years as it conducts advanced-stage clinical studies for SGT-610 and develops SGT-210[43]. - The company may need to raise substantial additional funding to pursue its business objectives, which could lead to dilution of shareholder value[43]. Product Development and Regulatory Approval - The company has not yet obtained regulatory approval for its product candidates in the United States or any other country, which poses a risk to its business[31]. - The company may face increased costs and delays in the marketing approval process if the FDA requires additional studies or data for its product candidates[49]. - The company expects to utilize the FDA's Section 505(b)(2) pathway for some product candidates, but if unavailable, development could take significantly longer and cost more[79]. - The company has filed two NDAs under Section 505(b)(2) of the FDCA, with Twyneo receiving FDA marketing approval in July 2021 and Epsolay in April 2022[189]. - The company may be required to perform additional clinical trials to support changes from branded reference drugs, potentially delaying regulatory approvals[192]. Market Competition and Commercialization - The company faces intense competition in the dermatology market, which may hinder its ability to achieve commercial success[31]. - The company’s future success is highly dependent on the market perception of its products and their safety and quality[31]. - The company faces significant competition for its product candidates, including SGT-610, Twyneo, and Epsolay, from established companies with greater resources and market experience[126][129]. - Sales of SGT-610, Twyneo, and Epsolay will depend heavily on third-party payor coverage and reimbursement levels, which are critical for profitability[135]. Clinical Trials and Patient Enrollment - The company may face challenges in enrolling patients for clinical trials, which could delay the development of its product candidates[31]. - The company faces intense competition for patient enrollment in clinical trials, which could delay or prevent the trials from proceeding[68]. - The company is dependent on ongoing clinical trials, and any delays could significantly harm its ability to generate product revenues[66]. - The company may experience delays in clinical trials due to various factors, including patient recruitment challenges and regulatory compliance issues[63]. Intellectual Property and Legal Risks - The company’s success is contingent on its ability to protect its intellectual property, which involves complex legal challenges[173]. - The company may face patent infringement lawsuits that could delay or prevent the review or approval of its product candidates[189]. - The company has granted licenses to third parties for its intellectual property, which may lead to increased competition and reduced market share[179]. - The company may incur substantial costs and management resource diversion due to legal proceedings related to intellectual property rights[183]. Regulatory Environment and Compliance - The company must comply with extensive regulatory requirements, including manufacturing and labeling, which could affect the commercial viability of its products[93]. - The enforcement of healthcare laws is uncertain and may change rapidly, complicating compliance efforts and diverting resources[141]. - The company faces risks related to compliance with healthcare regulatory laws, which could lead to significant penalties and operational impacts[139]. - Regulatory approval processes are lengthy and unpredictable, with the potential for changes in approval policies that could affect the company's product candidates[69]. Operational Challenges - The company relies on third-party partners for the commercialization of its products, which may affect its ability to achieve significant market penetration[31]. - The company is dependent on contract manufacturers for compliance with cGMP requirements, and any failure could jeopardize regulatory approvals[162]. - Manufacturing difficulties could significantly impact the ability to provide product candidates to patients and delay commercialization efforts[171]. - The company relies on third-party manufacturers for the production of product candidates and approved products, increasing risks related to supply and compliance[161]. External Factors and Risks - The company faces significant risks due to political, economic, and military conditions in Israel, which could adversely affect its operations and financial condition[196]. - Recent hostilities, including attacks from Hamas and Hezbollah, have escalated tensions in the region, potentially impacting the company's ability to conduct business[197]. - Exchange rate fluctuations between the U.S. dollar and the New Israeli Shekel may negatively impact future revenues, as a substantial portion of revenues is expected to be generated in foreign currencies[201]. - The company may face claims for remuneration or royalties for assigned service invention rights by employees, which could lead to litigation and adversely affect its business[211].

Financial Performance - Fourth quarter net sales were $695.1 million, an increase of 8.7% year-over-year, with Brand Portfolio sales up 20.3% and organic sales up 1.5%[5] - GAAP loss per diluted share was $0.70, while adjusted loss per diluted share was $0.36; excluding Stuart Weitzman, adjusted loss per diluted share was $0.06[5] - Gross profit for the fourth quarter was $290.3 million, with a gross margin of 41.8%, down 230 basis points compared to the previous year[8] - For fiscal 2026, total sales are expected to increase low to mid-single digits, with GAAP earnings per diluted share projected between $1.31 and $1.61[12] - First quarter 2026 guidance anticipates net sales to increase mid to high-single digits, with GAAP earnings per diluted share expected to be between $0.21 and $0.26[11] - Consolidated net sales for the same period reached $695.1 million, a 8.8% increase from $639.2 million in the prior year[27] - For the fiscal year ended January 31, 2026, consolidated net sales reached $2,757.9 million, a slight increase from $2,722.7 million in the previous year[31] Profitability and Margins - Gross profit for the thirteen weeks ended January 31, 2026, was $290,340, representing a gross margin of 41.7%, compared to $275,108 and a gross margin of 43.0% in the prior year[23] - The gross profit margin for the consolidated segment was 41.8%, down from 44.1% in the previous year[27] - Gross profit for the same period was $1,184.8 million, down from $1,222.0 million, resulting in a gross margin of 43.0%, compared to 44.9% in the prior year[31] - Adjusted gross profit, excluding Stuart Weitzman, was $1,152.3 million, reflecting a decrease from $1,222.0 million[32] - Operating earnings for the fiscal year were $6.4 million, significantly lower than $149.9 million in the previous year, with an operating margin of 0.2% compared to 5.5%[31] - The adjusted operating margin for the consolidated segment was -1.7%, compared to 0.2% in the prior year, reflecting operational challenges[27] Losses and Expenses - Operating loss for the thirteen weeks ended January 31, 2026, was $(26,473), a decline from operating earnings of $7,870 in the same period last year[23] - Net loss attributable to Caleres, Inc. for the thirteen weeks ended January 31, 2026, was $(22,734), compared to net earnings of $4,930 in the prior year[23] - Total charges and other items amounted to $14.9 million, impacting adjusted earnings negatively by $0.34 per share[26] - For the thirteen weeks ended January 31, 2026, Caleres reported a net loss of $24.3 million, compared to net earnings of $3.9 million for the same period in 2025[34] - The adjusted net loss for the same period was $13.3 million, while adjusted net earnings were $10.1 million in the prior year, indicating a significant decline[35] - For the fiscal year ended January 31, 2026, Caleres, Inc. reported a net loss of $9.9 million, down from net earnings of $106.1 million in the previous year[34] Sales by Segment - Famous Footwear sales declined 1.2%, while comparable sales were up 0.1%[5] - The Famous Footwear segment reported net sales of $354.0 million, slightly down from $358.4 million in the previous year, with a comparable sales increase of 0.1%[27] - The Brand Portfolio segment achieved net sales of $361.2 million, up from $300.3 million in the prior year, indicating a significant growth[27] - Stuart Weitzman net sales were $56.3 million for the thirteen weeks ended January 31, 2026, contributing to the overall financial results[27] Operational Metrics - Direct-to-consumer sales represented approximately 74% of total net sales in the fourth quarter[8] - The integration of Stuart Weitzman was completed on time and on budget, with minimal business disruption[5] - Selling and administrative expenses were $310.0 million, or 44.6% of net sales, reflecting a deleverage of 370 basis points compared to the previous year[8] - Inventory at year-end was $610.5 million, up $45.2 million year-over-year, with approximately $57 million attributed to Stuart Weitzman[14] - Total assets increased to $1,965,790 as of January 31, 2026, up from $1,894,754 as of February 1, 2025[24] - Total current liabilities increased to $845,540 as of January 31, 2026, from $757,933 as of February 1, 2025[24] - Cash and cash equivalents at the end of the period were $29,769, slightly up from $29,636 at the beginning of the period[25] - Net cash provided by operating activities for the thirteen weeks ended January 31, 2026, was $103,177, compared to $104,562 in the prior year[25] - The company incurred $108,858 in cash outflows for the acquisition of Stuart Weitzman during the period[25] - The company ended the period with 1,009 company-operated stores, an increase from 960 stores in the previous year[27] - The company operated 1,009 stores at the end of the fiscal year, an increase from 960 stores in the previous year[31] Shareholder Information - Basic loss per share attributable to Caleres, Inc. shareholders for the thirteen weeks ended January 31, 2026, was $(0.70), compared to earnings of $0.15 in the same period last year[23] - The diluted adjusted loss per common share, excluding Stuart Weitzman, was $(0.06) for the thirteen weeks ended January 31, 2026, compared to $0.33 in the prior year[36] - The company reported a total of 32.5 million basic common shares for the thirteen weeks ended January 31, 2026, slightly up from 32.5 million shares in the previous year[35] - Caleres, Inc. anticipates adjusted diluted earnings per share for fiscal 2026 to be between $1.35 and $1.65[38] - The company provided guidance for the first quarter of 2026, projecting GAAP diluted earnings per share between $0.21 and $0.26, and adjusted diluted earnings per share between $0.25 and $0.30[38]

Financial Performance - The net loss for the full year ended December 31, 2025, was $41.9 million, compared to $43.3 million in 2024, reflecting an operating loss of $40.1 million[9]. - Revenue for the year ended December 31, 2025, is reported at $500 million, compared to no revenue in 2024[21]. - Operating loss decreased to $40.1 million in 2025 from $47.4 million in 2024, indicating improved operational efficiency[21]. - Net loss for 2025 is $41.9 million, a slight improvement from a net loss of $43.3 million in 2024[21]. - Loss per share improved to $0.05 in 2025 from $0.06 in 2024, indicating a reduction in losses on a per-share basis[21]. - Total comprehensive loss for 2025 is $33.9 million, compared to $44.6 million in 2024, showing a reduction in overall losses[21]. - Other comprehensive income from foreign currency translation adjustments was $8.0 million in 2025, contrasting with a loss of $1.4 million in 2024[21]. - Interest income decreased to $2.2 million in 2025 from $3.0 million in 2024, indicating a decline in interest-earning assets[21]. - The company reported a benefit from research and development tax credit of $1.9 million in 2025, slightly up from $1.6 million in 2024[21]. Research and Development - Total research and development expenses decreased by $3.2 million from $20.9 million in 2024 to $17.8 million in 2025, primarily due to reductions in expenses for alvelestat and etigilimab[7]. - Research and development expenses decreased to $17.8 million in 2025 from $20.9 million in 2024, reflecting cost management efforts[21]. - Mereo anticipates a single Phase 3 trial enrolling approximately 220 patients for alvelestat, with a primary efficacy endpoint based on the St. George's Respiratory Questionnaire Total Score[5]. - Setrusumab demonstrated statistically significant improvements in bone mineral density and reductions in vertebral fractures in pediatric patients, although it did not achieve statistical significance against primary endpoints[5]. - Mereo has designed a potential Phase 2b study of alvelestat in bronchiectasis to support ongoing partnering discussions[5]. Corporate Developments - Mereo is in active discussions for the Phase 3 development and commercialization of alvelestat, with potential partners indicating progress[5]. - The company has retained EU and UK commercial rights for setrusumab while partnering with Ultragenyx, which includes potential milestone payments of up to $245 million[12]. - The total ordinary shares issued as of December 31, 2025, were 795,658,504, an increase from 775,728,034 in 2024[11]. - Weighted average shares outstanding increased to 797.1 million in 2025 from 739.6 million in 2024, suggesting potential dilution effects[21]. Expenses - General and administrative expenses decreased by $3.4 million from $26.4 million in 2024 to $23.0 million in 2025, attributed to lower accruals for bonuses and reduced professional fees[8].